Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 3/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093252 | 0.83 | BRD4 (0.69) | PLK1BRD4KDM4EL3MBTL1PTPN7 | |
| SCHEMBL28068133 | 0.81 | PLK1 (0.57) | PLK1BRD4KDM4EL3MBTL1PTPN7 | |
| SCHEMBL20674165 | 0.80 | SMN1; SMN2 (0.55) | BRD4L3MBTL1LMNAPOLBCREBBP | |
| SCHEMBL30117222 | 0.79 | LMNA (0.74) | PLK1BRD4L3MBTL1PTPN7NR4A2 | |
| SCHEMBL10596904 | 0.78 | KDM4E (0.50) | KDM4EL3MBTL1NR4A2LMNACNR1 | |
| SCHEMBL14118735 | 0.78 | ALDH1A1 (0.50) | PLK1KDM4ELMNAPOLBHTT | |
| SCHEMBL19234284 | 0.76 | PTPN7 (0.61) | PLK1BRD4KDM4EL3MBTL1PTPN7 | |
| SCHEMBL13837161 | 0.76 | KMT2A (0.69) | PLK1KDM4EPTPN7LMNACNR1 | |
| SCHEMBL10341234 | 0.76 | KDM4E (0.72) | BRD4KDM4EL3MBTL1NR4A2LMNA | |
| SCHEMBL8999130 | 0.74 | PLK1 (1.00) | PLK1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | PLK1 322/4885BRD4 2555/4885KDM4E 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.